statistiche ricercatore

Continente	#
NA - Nord America	655
AS - Asia	513
EU - Europa	421
SA - Sud America	78
Continente sconosciuto - Info sul continente non disponibili	33
AF - Africa	27
OC - Oceania	8
Totale	1.735

Nazione	#
US - Stati Uniti d'America	630
IT - Italia	218
SG - Singapore	163
CN - Cina	89
VN - Vietnam	66
BR - Brasile	57
BD - Bangladesh	42
DE - Germania	32
HK - Hong Kong	31
KR - Corea	31
FR - Francia	30
IN - India	30
NL - Olanda	25
SE - Svezia	24
FI - Finlandia	13
MA - Marocco	13
PL - Polonia	13
TR - Turchia	13
CA - Canada	12
IE - Irlanda	10
AR - Argentina	9
RO - Romania	9
RU - Federazione Russa	9
AU - Australia	8
GB - Regno Unito	8
MX - Messico	8
ZA - Sudafrica	8
AT - Austria	7
JP - Giappone	7
ID - Indonesia	5
IR - Iran	5
PH - Filippine	5
EC - Ecuador	4
EG - Egitto	4
ES - Italia	4
IQ - Iraq	4
BE - Belgio	3
JO - Giordania	3
PK - Pakistan	3
BG - Bulgaria	2
BO - Bolivia	2
CH - Svizzera	2
CL - Cile	2
CO - Colombia	2
DZ - Algeria	2
GR - Grecia	2
LB - Libano	2
SA - Arabia Saudita	2
SK - Slovacchia (Repubblica Slovacca)	2
TW - Taiwan	2
UZ - Uzbekistan	2
AE - Emirati Arabi Uniti	1
BB - Barbados	1
CR - Costa Rica	1
CZ - Repubblica Ceca	1
DK - Danimarca	1
DO - Repubblica Dominicana	1
GE - Georgia	1
IL - Israele	1
JM - Giamaica	1
KG - Kirghizistan	1
LK - Sri Lanka	1
LT - Lituania	1
LV - Lettonia	1
MD - Moldavia	1
MY - Malesia	1
NI - Nicaragua	1
NP - Nepal	1
OM - Oman	1
PE - Perù	1
PT - Portogallo	1
SI - Slovenia	1
UA - Ucraina	1
VE - Venezuela	1
Totale	1.702

Nome	#
Glypican 1-targeted therapeutic approaches adopting doxorubicin-loaded chitosan nanobubbles and antibody-based strategy in the context of Pancreatic Ductal Adenocarcinoma	367
A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma	179
A novel epigenetic machine learning model to define risk of progression for hepatocellular carcinoma patients	178
New insight into therapies targeting angiogenesis in hepatocellular carcinoma	165
Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies	164
The anti-glypican 1 AT101 antibody as targeting agent to effectively deliver chitosan nanobubbles to glioblastoma cells.	162
Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma	149
The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma	126
Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer	125
Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies	103
Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models	17
Totale	1.735

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	40	0	0	3	0	0	0	0	1	1	1	1	33
2022/2023	115	4	12	5	13	18	18	0	16	17	4	3	5
2023/2024	98	17	6	5	4	4	10	17	18	1	6	10	0
2024/2025	377	9	10	11	41	19	36	27	31	37	47	56	53
2025/2026	965	113	38	134	104	75	50	109	31	100	91	74	46
2026/2027	126	47	50	29	0	0	0	0	0	0	0	0	0
Totale													1.735

ArTS Archivio della ricerca di Trieste